|
|
Volumn 3, Issue 2, 2004, Pages 103-105
|
|
2003 approvals: A year of innovation and upward trends
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BORTEZOMIB;
ENFUVIRTIDE;
EPIDERMAL GROWTH FACTOR RECEPTOR;
GEFITINIB;
MEMANTINE;
MONOCLONAL ANTIBODY;
N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;
OMALIZUMAB;
OXYCODONE;
PROTEASOME INHIBITOR;
PROTEIN TYROSINE KINASE;
TELITHROMYCIN;
XIMELAGATRAN;
ALLERGIC ASTHMA;
ALZHEIMER DISEASE;
ARTICLE;
CELL FUSION;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG FATALITY;
DRUG INDUSTRY;
DRUG INFORMATION;
DRUG RESEARCH;
DRUG SAFETY;
DRUG TARGETING;
ENZYME ACTIVITY;
ENZYME INHIBITION;
EUROPE;
FINANCIAL MANAGEMENT;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
LICENSING;
LUNG NON SMALL CELL CANCER;
MULTIPLE MYELOMA;
PRESCRIPTION;
PRIORITY JOURNAL;
TARGET CELL;
UNITED STATES;
VIRUS TRANSMISSION;
|
|
EID: 1242330795
PISSN: 14741776
EISSN: None
Source Type: Journal
DOI: 10.1038/nrd1327 Document Type: Article |
|
Times cited : (17)
|
|
References (0)
|